Drug firms await India court decision on patent protection

03/27/2013 | Economic Times (India), The

Pharmaceutical companies are awaiting a decision from India's Supreme Court, due April 1, that could determine the state of intellectual property protection for branded drugs in India. The case involves whether an amended form of Novartis' cancer treatment Glivec, used to treat chronic myeloid leukemia, is entitled to patent protection against generic competitors. "Big Pharma is nervous because nothing has gone in their favour in the recent past," said pharmaceutical consultant Ajay Kumar Sharma.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
MEDICAL SCIENCE LIAISON - 14000002RO
Abbott
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Abbott
Santa Ana, CA